ClinicalTrials.gg
RecruitingNCT06919081Updated Oct 28, 2026

Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease

A Phase 2 interventional study of Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome and Vehicle Control in Persistent Corneal Epithelial Defect and Corneal Epithelial Disorders, sponsored by University of Illinois Chicago. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by University of Illinois Chicago · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 28, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In this phase II randomized double-masked clinical trials, subjects with non-resolving corneal epithelial disease/defect (i.e., refractory to standard treatments for at least two weeks) will receive 8 weeks treatment of topical mesenchymal stem cell secretome or vehicle, with continued follow-up for up to Day 70.

02

Conditions studied

  • Persistent Corneal Epithelial Defect
  • Corneal Epithelial Disorders

Keywords

  • persistent corneal epithelial disease/defects
  • persistent corneal epithelial
  • corneal epithelial disease
  • limbal stem cell deficiency
  • neurotrophic keratitis
03

In context

Limbal Stem Cell Deficiency

38 studies on the registry are indexed under Limbal Stem Cell Deficiency; 15 are open to participants now.

This study's planned enrollment of 24 is above the median of 20 across 23 interventional studies indexed under Limbal Stem Cell Deficiency.

Browse Limbal Stem Cell Deficiency studies →

Lead sponsor

University of Illinois Chicago is the lead sponsor of 31 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age · Patients 18 years of age or older
  • Ocular Health

    • Chronic corneal epithelial disease with fluorescein staining score 6 by NEI grading scale or persistent corneal epithelial defect present for longer than 14 days despite standard treatment
    • No objective clinical evidence of significant (> 50%) improvement/worsening of the epithelial disease in the last 14 days
    • Epithelial disease to conventional non-surgical treatments (e.g., preservative-free artificial tears, gels or ointments; discontinuation of preserved topical drops; anti-inflammatory therapy)
    • If both eyes of subject meet the inclusion criteria, the eye with the higher fluorescein staining score will be enrolled to the study.
  • Study Procedures

    • Only patients who satisfy all requirements may be included in the study. The patient and/or his/her legal representative must read, sign and date the Informed Consent document before any study-related procedures are performed. The Informed Consent form signed by patients and/or legal representative must have been approved by the UIC IRB for the current study. Patients must have the ability and willingness to comply with study procedures.

Exclusion criteria

Exclusion Criteria:

  • Ocular Health

    • Any active or suspected ocular infection (bacterial, viral, fungal or protozoal).
    • History of any ocular surgery (including laser or refractive surgical procedures) in the study eye within the 3 months prior to study enrollment.
    • Treatment with Oxervate in the study eye within 12 months of enrollment.
  • Study Procedures

    • Known to one of the components of the study or procedural medications (e.g., fluorescein).
    • Use of any agent within 4 weeks of screening visit.
    • Participation in another clinical study at the same time as the present study.
    • Participants who are pregnant at the time of study enrollment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome

    Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome for Topical Eye Drop

    Drug: Allogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome

  • Placebo comparator
    Vehicle

    Vehicle (unconditioned media)

    Other: Vehicle Control

Interventions

  • DrugAllogeneic Bone-Marrow Derived Mesenchymal Stromal Cells Secretome

    Eye Drops

  • OtherVehicle Control

    Eye Drops

06

What researchers measure

Primary outcomes

  1. Improvement of Corneal Epithelial Barrier and/or Integrity (Efficacy Outcome)

    Proportion of subjects with improved epithelial barrier and/or integrity from baseline to DAY 56 as determined by the investigator on slit lamp examination: · Improved epithelial barrier, defined as ³ 50 % improvement in corneal fluorescein staining score using NEI grading scale · Improved epithelial integrity, defined as complete closure of persistent epithelial defect, measured with ImageJ on slit lamp images

    Time frame: Baseline to Day 56

Secondary outcomes

  1. Visual Acuity

    Percent change in best-corrected distance visual acuity from baseline to DAY 56 as measured using standard ETDRS protocols

    Time frame: Baseline to Day 56

  2. Corneal staining and NEI grading

    Grading of fluorescein staining of the cornea Minimum score = 0 Maximum score = 15 Lower score is better

    Time frame: Baseline to Day 70

  3. Ocular Surface Parameters

    Changes in ocular surface disease index (OSDI) from baseline to DAY 56 and DAY 70 Minimum value = 0 Maximum value = 100 Lower value is better

    Time frame: Baseline to Day 70

  4. Corneal Epithelial Thickness

    Percent change in corneal epithelial thickness from baseline to DAY 56 and DAY 70, as measured by anterior segment OCT (AS-OCT)

    Time frame: Baseline to Day 70

  5. Subject Symptoms

    Changes in ocular discomfort visual analog scale (VAS) 0 - 100, where 0 is no discomfort and 100 the worst discomfort, from baseline to DAY 70

    Time frame: Baseline to Day 70

  6. Time to epithelial healing

    Time of improvement of epitheliopathy

    Time frame: Baseline to Day 70

  7. Corneal Opacities/Scars

    Change in the size of corneal opacities and scars (if present) from baseline to DAY 56 as documented by slit lamp photographs

    Time frame: Baseline to Day 56

  8. Corneal vascularization

    Change in corneal vascularization on slit lamp photographs from baseline to DAY 56

    Time frame: Baseline to Day 56

  9. Conjunctival injection

    Change in conjunctival injection on slit lamp examination from baseline to DAY 56

    Time frame: Baseline to Day 56

  10. Subbasal corneal nerve density

    Changes in subbasal corneal nerve density on confocal microscopy from baseline to Day 56

    Time frame: Baseline to Day 56

  11. Ocular Surface Parameters

    Changes in Lissamine green staining from baseline to DAY 56 and DAY 70

    Time frame: Baseline to Day 70

  12. Ocular Surface Parameters

    Changes in anesthetic Schirmer's test from baseline to DAY 56 and DAY 70

    Time frame: Baseline to Day 70

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Mar 2026 → Dec 2026 and completion Jun 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2025
First posted
Apr 9, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Dec 15, 2026was Mar 2026
CompletionEst.
Dec 15, 2026was Jun 2026
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Mar 15, 2026→Dec 15, 2026
Oct 28, 2026
Study completion
Jun 15, 2026→Dec 15, 2026
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Primary completion Mar 15, 2026→Dec 15, 2026
    Study completion Jun 15, 2026→Dec 15, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06919081
Lead sponsor
University of Illinois Chicago
Responsible party
Ali R Djalilian (Principal Investigator, University of Illinois Chicago) — Principal investigator
First posted
Apr 9, 2025
Start date
Aug 1, 2025
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Oct 28, 2026

Study contacts

Ali R Djalilian, MD
Contact
adjalili@uic.edu
3129968937
Charlotte E Joslin, OD
Contact
charjosl@uic.edu
3129965410
Ali R Djalilian, MD
principal investigator · University of Illinois Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion